5-Bromo-2-((2-chloro-4-iodophenyl)amino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide 5-溴-2-((2-氯-4-碘苯基)氨基)-N-(环丙基甲氧基)-3,4-二氟苯甲酰胺

CAS 212631-67-9 MFCD16038897

化学结构图

212631-67-9
SMILES: O=C(NOCC1CC1)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1Cl

化学属性

Mol. Weight557.55
Mol. FormulaC17H13BrClF2IN2O2
Appearance Solid powder
SolubilitySoluble in DMSO

别名和识别编码

Synonym 5-Bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benzamide 5-Bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benzamide PF-1529483 PF-3011370 UK-287074 PD184161; PD 184161; PD184161; PF1529483 PF3011370 UK287074. PF-1529483 PF-3011370 UK-287074
MDL NumberMFCD16038897
CAS Number212631-67-9
Chemical Name5-Bromo-2-((2-chloro-4-iodophenyl)amino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide
PubChem Substance ID329823704
Chemical Name Translation5-溴-2-((2-氯-4-碘苯基)氨基)-N-(环丙基甲氧基)-3,4-二氟苯甲酰胺
FormulaC17H13BrClF2IN2O2
IUPAC Name2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide
InChIKeyVJNZMSLGVUSPCF-UHFFFAOYSA-N
InChIInChI=1S/C17H13BrClF2IN2O2/c18-11-6-10(17(25)24-26-7-8-1-2-8)16(15(21)14(11)20)23-13-4-3-9(22)5-12(13)19/h3-6,8,23H,1-2,7H2,(H,24,25)
Canonical SMILESO=C(NOCC1CC1)C2=CC(Br)=C(F)C(F)=C2NC3=CC=C(I)C=C3Cl
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

分类

  • {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Kinase/Phosphatase Biology, Mitogen-Activated Protein Kinase Kinase (MAPKK), P-PH, Pfizer Compounds, Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
  • Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience, Kinase/Phosphatase Biology, Mitogen-Activated Protein Kinase Kinase (MAPKK), P, Pfizer Compounds, Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors

产品应用

  • PD184161 is an orally-active MEK inhibitor. PD184161 inhibited MEK activity (IC50 = 10-100 nM) in a time- and concentration-dependent manner more effectively than PD098059 or U0126. PD184161 inhibited cell proliferation and induced apoptosis at concentrations of > or = 1.0 microM in a time- and concentration-dependent manner. PD184161 has antitumor effects in HCC in vitro and in vivo that appear to correlate with suppression of MEK activity. PD184161 is unable to suppress MEK activity in HCC xenografts in the long term.

相关文献及参考

  • Yip-Schneider, M.T., et al., Resistance to mitogen-activated protein kinase kinse (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 329 , 1063-1070, (2009)
  • Choi, J., et al., The effect of doxorubicin on MEK-ERK signaling predicts its efficacyin HCC. J. Surg. Res. 150 , 219-226, (2008)
  • Duman, C.H., et al., A role for MAP kinase signaling in hehavioral models of depression and antidepressant treatment. Biol. Psychiatry 61 , 661-670, (2007)

安全信息

GHS Symbol
Precautionary statements
  • P273 Avoid release to the environment. 避免释放到环境中。
Signal word Warning
Hazard statements
  • H400 Verytoxictoaquaticlife 对水生生物毒性非常大。
WGK Germany3
Storage condition Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

系列性分类

  1. Life Science 生命科学
  2. Cell Biology 细胞生物学
  3. Cell Signaling and Neuroscience - Cell Biology
  4. Kinase/Phosphatase Biology - Cell Signaling and Neuroscience
  5. Serine/Threonine Kinase Biology - Kinase/Phosphatase Biology
  6. Serine/Threonine Kinase Inhibitors - Serine/Threonine Kinase Biology
  7. Mitogen-Activated Protein Kinase Kinase (MAPKK) - Serine/Threonine Kinase Inhibitors
  1. Medical Research Areas
  2. MARK
  3. MEK

相关产品推荐